68Ga-prostate-specific membrane antigen (PSMA) and 68Ga-DOTA0-Tyr3-octreotate (DOTATATE) positron emission tomography/computed tomography (PET/CT) in a case of metastatic castration-resistant prostate cancer (mCRPC) with low prostate-specific antigen (PSA) and reduced 18F-fluorodeoxyglucose (FDG) uptake after endocrine therapy

请注册登录后继续浏览